↓ Skip to main content

Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability

Overview of attention for article published in BMC Psychiatry, November 2016
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
22 Dimensions

Readers on

mendeley
91 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability
Published in
BMC Psychiatry, November 2016
DOI 10.1186/s12888-016-1115-z
Pubmed ID
Authors

Giulia Malaguarnera, Gaetano Bertino, Giuseppe Chisari, Massimo Motta, Michele Vecchio, Marco Vacante, Filippo Caraci, Carmela Greco, Filippo Drago, Giuseppe Nunnari, Michele Malaguarnera

Abstract

Hepatitis C virus infection and interferon treatment are often associated with anxiety, depressive symptoms and poor health-related quality of life. To evaluate the Silybin-vitamin E-phospholipids complex effect on work ability and whether health related factors (anxiety and depression) were associated with work ability in subjects with chronic hepatitis C treated with Pegylated-Interferon-α2b (Peg-IFN) and Ribavirin (RBV). Thirty-one patients (Group A) with chronic hepatitis and other 31 subjects in Group B were recruited in a randomized, prospective, placebo controlled, double blind clinical trial. Group A received 1.5 mg/kg per week of Peg-IFN plus RBV and placebo, while Group B received the same dosage of Peg-IFN plus RBV plus association of Silybin 94 mg + vitamin E 30 mg + phospholipids 194 mg in pills for 12 months. All subjects underwent to laboratory exams and questionnaires to evaluate depression (Beck Depression Inventory - BDI), anxiety (State-trait anxiety inventory - STAI) and work ability (Work ability Index - WAI). The comparison between group A and group B showed significant differences after 6 months in ALT (P < 0.001), and viremia (P < 0.05), after 12 months in ALT (P < 0.001), and AST (P < 0.001), at follow up in AST (P < 0.05), and ALT (P < 0.001). Significant difference were observed after 1 month in WAI (p < 0.001) and BDI (P < 0.05), after 6 months in WAI (P < 0.05) and STAI (P < 0.05), after 12 months and at follow up in WAI, STAI and BDI (p < 0.01). The supplementation with Silybin-vitamin E -phospholipids complex increased work ability and reduced depression and anxiety in patients treated with Peg-IFN and RBV. NCT01957319 , First received: September 25, 2013. Last updated: September 30, 2013 (retrospectively registered).

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 91 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 1%
Unknown 90 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 10 11%
Researcher 9 10%
Student > Bachelor 9 10%
Student > Ph. D. Student 6 7%
Student > Postgraduate 5 5%
Other 18 20%
Unknown 34 37%
Readers by discipline Count As %
Medicine and Dentistry 15 16%
Nursing and Health Professions 11 12%
Psychology 8 9%
Biochemistry, Genetics and Molecular Biology 4 4%
Pharmacology, Toxicology and Pharmaceutical Science 4 4%
Other 10 11%
Unknown 39 43%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 November 2016.
All research outputs
#20,353,668
of 22,901,818 outputs
Outputs from BMC Psychiatry
#4,233
of 4,711 outputs
Outputs of similar age
#265,073
of 306,451 outputs
Outputs of similar age from BMC Psychiatry
#79
of 85 outputs
Altmetric has tracked 22,901,818 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,711 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 306,451 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 85 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.